Back to Search Start Over

Coronary sinus reducer for the treatment of refractory angina (ORBITA-COSMIC): a randomised, placebo-controlled trial

Authors :
Foley, Michael J
Rajkumar, Christopher A
Ahmed-Jushuf, Fiyyaz
Simader, Florentina A
Chotai, Shayna
Pathimagaraj, Rachel H
Mohsin, Muhammad
Salih, Ahmed
Wang, Danqi
Dixit, Prithvi
Davies, John R
Keeble, Tom R
Cosgrove, Claudia
Spratt, James C
O’Kane, Peter D
De Silva, Ranil
Hill, Jonathan M
Nijjer, Sukhjinder S
Sen, Sayan
Petraco, Ricardo
Mikhail, Ghada W
Khamis, Ramzi
Kotecha, Tushar
Harrell, Frank E
Kellman, Peter
Francis, Darrel P
Howard, James P
Cole, Graham D
Shun-Shin, Matthew J
Al-Lamee, Rasha K
Source :
The Lancet; April 2024, Vol. 403 Issue: 10436 p1543-1553, 11p
Publication Year :
2024

Abstract

The coronary sinus reducer (CSR) is proposed to reduce angina in patients with stable coronary artery disease by improving myocardial perfusion. We aimed to measure its efficacy, compared with placebo, on myocardial ischaemia reduction and symptom improvement.

Details

Language :
English
ISSN :
01406736 and 1474547X
Volume :
403
Issue :
10436
Database :
Supplemental Index
Journal :
The Lancet
Publication Type :
Periodical
Accession number :
ejs66109620
Full Text :
https://doi.org/10.1016/S0140-6736(24)00256-3